www.StockMarketingInc.com: Our Newsletter Is On Fire!! Sign Up Now!! ISPH,NEXM,QLTI,BRYN,HESG,AENY

www.StockMarketingInc.com

To sign up for our free Profiles & Alerts :: visit http://www.StockMarketingInc.com

email us!! info@StockMarketingInc.com or call 1-866-583-8960

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NASDAQ: ISPH - Inspire Pharmaceuticals, Inc.)

LATEST NEWS!!

Inspire Announces Webcast of Presentation at Piper Jaffray Health Care Conference

DURHAM, N.C., Nov 25, 2009 -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH | Quote | Chart | News | PowerRating) announced today that Christy L. Shaffer, Ph.D., President and CEO, and Thomas R. Staab, II, CFO and Treasurer, will present at the 21st Annual Piper Jaffray Health Care Conference on Wednesday, December 2, 2009 at 10:00 am ET in New York City.

The webcast of the presentation will be available on Inspire's web site at www.inspirepharm.com. An archived version of the webcast presentation will also be available through this link for a limited time following the conference.

About Inspire Inspire is a biopharmaceutical company focused on researching, developing and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases. Inspire's goal is to build and commercialize a sustainable portfolio of innovative new products based on its technical and scientific expertise. The most advanced compounds in Inspire's clinical pipeline are PROLACRIA(TM) (diquafosol tetrasodium ophthalmic solution) 2% for dry eye and denufosol tetrasodium for cystic fibrosis, which are both in Phase 3 development and AZASITE(R) (azithromycin ophthalmic solution) 1% for blepharitis, which is in Phase 2 development. Inspire receives revenues related to the promotion of AZASITE for bacterial conjunctivitis, the co-promotion of ELESTAT(R) (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and royalties based on net sales of RESTASIS(R) (cyclosporine ophthalmic emulsion) 0.05% for dry eye. For more information, visit www.inspirepharm.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NASDAQ: NEXM - NexMed, Inc.)

LATEST NEWS!!

NexMed, Inc. to Acquire Bio-Quant, Inc.

Cash Flow Positive, Growing Business Provides NexMed with Pre-clinical Capabilities, Added Licensing Expertise and Critical Mass;

EAST WINDSOR, N.J., Nov 23, 2009 --Transaction May Enable Continued NASDAQ Listing --Conference Call to Be Held at 9:00 am EST Today NexMed, Inc. (Nasdaq: NEXM), a developer of products based on the NexACT(R) technology, today announced that it has entered into a definitive agreement to acquire Bio-Quant, Inc., a revenue generating privately-held leading research organization for in vitro and in vivo contract drug discovery and pre-clinical development services, headquartered in San Diego, CA. Upon closing of the transaction, which is expected before the end of the year, Bio-Quant will become a wholly-owned subsidiary of NexMed. Bassam Damaj, Ph.D., co-founder, current Chief Executive Officer and Chief Scientific Officer of Bio-Quant, will become Chief Executive Officer of NexMed, replacing Vivian Liu, who will transition to the role of Executive Vice President and, in that capacity, Ms. Liu will continue to be responsible for leading the business development and licensing efforts for NexMed's clinical programs. Mark Westgate will remain as NexMed's Chief Financial Officer. The Board will be composed of three Bio-Quant nominees and four NexMed nominees, and Ms. Liu is expected to be appointed as Chairman of the Board.

The agreement provides for NexMed's issuance of 4,000,000 unregistered shares of its common stock to the Bio-Quant shareholders and a promissory note (the "Note") in the amount of approximately $12.1 million due on December 31, 2010. NexMed can elect to pay all or any portion of the Note by issuing its common stock. Such repayment in common stock is contingent upon NexMed shareholder approval. As a condition to closing, there will be a Bio-Quant shareholders meeting. Certain key shareholders of Bio-Quant have agreed to vote in favor of the transaction.

Commenting on today's news, Ms. Liu stated, "We look forward to welcoming the Bio-Quant team as a NexMed subsidiary. Through this transaction, NexMed acquires a revenue generating, cash flow positive business which has grown over 250% in the past five years and is continuing to grow at present. Moreover, we will gain preclinical capabilities, add valuable licensing expertise and be able to leverage Bio-Quant's existing relationships with key pharmaceutical companies -- all of which will aid in the continued development and the ultimate commercialization of our products under development." Dr. Damaj, noted, "We are delighted to become part of NexMed, a company with a novel technology and innovative products which we believe can be better monetized and generate value for our shareholders. While continuing our normal course of business as a leading CRO, we will be adding Our established and growing business, resources, and expertise to NexMed, which should allow NexMed to continue its business development in a more rapid and efficient manner." Mark Westgate added, "The acquisition of Bio-Quant was an integral part of our compliance plan presented to the NASDAQ Listing Qualification Panel (the "Panel") on Thursday, November 12, 2009. We are hopeful that the signing of this agreement will give the Panel further confidence that we will regain and maintain compliance with all applicable continued listing requirements. While we have yet to receive a decision from the Panel, we are optimistic that the Panel will continue our listing pending the implementation of our plan." FTN Equity Capital Markets Corp., in New York City, has served as NexMed's financial advisor in the structuring and negotiations of this transaction.

Conference Call The Company will hold a conference call to discuss this announcement, today, Monday, November 23, 2009 at 9:00 am EST. The call can be accessed in the U.S. by dialing 877-407-9205 and outside of the U.S. by dialing 201-689-8054 and asking the conference operator for the NexMed Conference Call. The teleconference replay is available for one week by dialing in the U.S. 877-660-6853 and outside of the U.S. by dialing 201-612-7415. Replay pass codes 286 and 338281 are both required for playback. The conference call will also be Webcast live at URL http://www.investorcalendar.com/IC/CEPage.asp?ID=152583. The Webcast replay will be available for three months.

About NexMed NexMed's pipeline includes a late stage terbinafine treatment for onychomycosis, a late stage alprostadil treatment for erectile dysfunction, a Phase 2 alprostadil treatment for female sexual arousal disorder, and an early stage treatment for psoriasis. For further information, go to www.nexmed.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NASDAQ: QLTI - QLT, Inc.)

LATEST NEWS!!

QLT announces MGH litigation settlement

VANCOUVER, Nov. 25, 2009 -- QLT Inc. (NASDAQ: QLTI; TSX: QLT) ("QLT" or the "Company") today announced the settlement of its litigation with the General Hospital Corporation, doing business as Massachusetts General Hospital ("MGH"). Under the terms of the settlement agreement, QLT will pay US$20.0 million to MGH as payment in full for all past and future royalty obligations under the License Agreement between QLT and MGH, in exchange for the dismissal with prejudice of MGH's lawsuit against QLT pending in the Massachusetts District Court for violation of Massachusetts General Law Chapter 93A, sections 2 and 11. As part of the settlement, QLT and MGH have also released each other from any claims in connection with the lawsuit and certain related matters. Under the existing License Agreement, QLT was obligated to pay MGH a 0.5% royalty on Visudyne(R) sales in the U.S. and Canada.

"We are pleased to put this matter behind us and continue to concentrate on our clinical programs and strategic growth initiatives," said Bob Butchofsky, President and Chief Executive Officer of QLT. "We believe that this agreement fairly resolves our dispute and serves to recognize the critically important contributions made by MGH in the development of Visudyne." About QLT QLT Inc. is a pharmaceutical company dedicated to the development and commercialization of innovative therapies for the eye. We are focused on our commercial product Visudyne(R) for the treatment of wet-AMD, and the development of drugs to be delivered in our proprietary punctal plug devices. For more information, visit our website at www.qltinc.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(PINKSHEETS: BRYN - Bryn Resources, Inc.)

LATEST NEWS!!

Bryn Resources Inc Finalizes the form of a Letter of Intent with holder of Mineralized claims in Quebec

TORONTO, Nov 25, 2009 -- Bryn Resources Inc (PINKSHEETS: BRYN | Quote | Chart | News | PowerRating) (PINKSHEETS: BRYN.PK) is pleased to announce that it has finalized the form of a Letter of Intent with Dominic Gingras the owner of 22 mining titles known as The Montauban 4 property, which cover 528.02 hectares North of Quebec City, Quebec.

The Letter of Intent will be signed today and will outline the terms pursuant to which Bryn Resources will acquire a 60% interest in the aforementioned mining titles.

It is the intention of Bryn Resources to carry out further exploratory investigations to complete the evaluation of the reserves in the property which investigation was started in 2003 by Mirabel Resources.

The initial investigations undertaken have revealed measured and indicated resources including 398,033 tonnes at a grade of 3.02 g/t Au and 27.72 g/t Ag for a total of 38,832 ounces of gold and 356,886 ounces of silver. Bryn Resources intends to complete further bulk sampling of the property so as to confirm the resources estimated.

Bryn Resources views this future acquisition as a forward looking business venture that will increase the shareholder value of its stock. Bryn Resources continues to seek other proven mineralized properties and expects to expand its holdings through future acquisitions.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(PINKSHEETS: HESG - Health Sciences Group, Inc.)

LATEST NEWS!!

INDIAN HARBOR BEACH, Fla., Nov 23, 2009 -- Health Sciences Group, Inc. (Pink Sheets:HESG) would like to announce that:

1. The Company has retained the accounting firm of RR Hawkins and associates to first complete the company's financials to be in accordance with pinksheets.com for purposes of moving up from limited information to current information. This process will also aid in moving to the otcbb 2. The Company has identified several properties in the Los Angeles area for offices.

3. The company's lawyer Robert Young has obtained the proper applications for marijuana dispensaries in LA County.

ABOUT HEALTH SCIENCES GROUP, INC.

Health Sciences Group, Inc. is a provider of health and wellness services to consumers, physicians and other healthcare professionals through its website, www.igohealthy.org, and health focused publications. The Health Sciences network consists of its public website, www.igohealthy.org, and iGoHealthy Magazine. The Company operates in three segments: Online Services, Publishing and Other Services. The Company is recently exploring options of corporate growth within the Legal Medical Marijuana Industry.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(OTCBB: AENY - Americas Energy Company)

LATEST NEWS!!

Americas Energy Company - Tennessee Signs Agreement to Purchase Evan's Coal Company, Inc.

KNOXVILLE, TN, Nov 24, 2009 -- Americas Energy Company (OTCBB: AENY), a publicly traded company currently based out of British Columbia, and Americas Energy Company, Inc. "AECo," based out of Knoxville, Tennessee, announced today that AECo has entered into an agreement to purchase the assets of 38-year-old Evans Coal Company, Inc. (Evan's), based in Flat Lick, Kentucky. AECo is in the process of being acquired by AENY. AECo began initial mine production on Evan's Upland Church Surface Mine in October of this year and has been negotiating to acquire the balance of their assets. The acquisition includes leased mineral rights to an estimated 25,000 +/- acres of property located in Bell, Harlan, Knox and Breathitt County, Kentucky, 60+ pieces of heavy equipment, and three generations of community service.

"The purchase of Evan's Coal Company will be a major milestone for our company. We are not only acquiring a major specialty coal reserve in Southeastern Kentucky, but more than 40 years of goodwill in the Flat Lick, Pineville, Kentucky area. Mr. John Gargis, our Executive Vice President, is overseeing the production from the Upland Church mine as well as the acquisition of Evans Coal Company," said Chris Headrick, President and Co-CEO of Americas Energy Company. Mr. Headrick added, "We plan to maintain that strong community presence and develop the assets the Evan's family assembled over the last 15 years. Evan's has an enormous high-grade specialty coal reserve that includes Kentucky Blue Gem, Jellico and the Harlan coal seams. We are also acquiring two additional Mining Permits that will allow us to immediately begin expanding our specialty coal production. Mr. Gargis plans to begin operations on the Hwy 92 permit in the first weeks of December in the Upper and Lower Rooster coal seams producing an estimated 15,000-20,000 short tons of coal per month. We also plan initiate an aggressive drilling plan to further identify our reserve base of high-grade specialty coal across the property. " About Americas Energy Company We are a consolidator of high quality energy properties, operating out of our main offices in Knoxville, TN. We currently operate projects in both Kentucky and Tennessee. AECo invests in energy projects throughout the Americas. We are currently evaluating several additional coal projects, as well as an oil and gas rework project in Southeastern Kentucky.

------------------------------------------------------------------------------------------------------------------------------------------------------------

About StockMarketingInc.com

StockMarketingInc.com is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by StockMarketingInc.com. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.

CONTACT: StockMarketingInc.com
e-mail: info@StockMarketingInc.com
Tel: +1 866 583 8960

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

For full details on (BRYN) BRYN. (BRYN) has Short Term PowerRatings at TradingMarkets. Details on (BRYN) Short Term PowerRatings is available at This Link.

For full details on Qlt Inc (QLTI) QLTI. Qlt Inc (QLTI) has Short Term PowerRatings at TradingMarkets. Details on Qlt Inc (QLTI) Short Term PowerRatings is available at This Link.

For full details on Nexmed Inc (NEXM) NEXM. Nexmed Inc (NEXM) has Short Term PowerRatings at TradingMarkets. Details on Nexmed Inc (NEXM) Short Term PowerRatings is available at This Link.

For full details on Inspire Pharmaceuticals (ISPH) ISPH. Inspire Pharmaceuticals (ISPH) has Short Term PowerRatings at TradingMarkets. Details on Inspire Pharmaceuticals (ISPH) Short Term PowerRatings is available at This Link.

For full details on (HESG) HESG. (HESG) has Short Term PowerRatings at TradingMarkets. Details on (HESG) Short Term PowerRatings is available at This Link.

For full details on (AENY) AENY. (AENY) has Short Term PowerRatings at TradingMarkets. Details on (AENY) Short Term PowerRatings is available at This Link.